12:00 AM
 | 
Sep 27, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MVA-HPV-IL2: Began Phase I trial

Transgene S.A. (NM:Transgene; TRGNY), Strasbourg, France
Product: MVA-HPV-IL2
Business: Gene/Cell therapy
Therapeutic category: Gene therapy
Target: Immune...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >